• 1
    Wang Z, Hoy WE. Population distribution of high sensitivity C-reactive protein values in Aboriginal Australians: a comparison with other populations. Clin Biochem. 2006;39(3):27781.
  • 2
    Rowley K, Walker KZ, Cohen J, Jenkins AJ, O'Neal D, Su Q, et al. Inflammation and vascular endothelial activation in an Aboriginal population: relationships to coronary disease risk factors and nutritional markers. Med J Aust. 2003;178(10):495500.
  • 3
    McDonald S, Maguire G, Duarte N, Wang XL, Hoy W. C-reactive protein, cardiovascular risk, and renal disease in a remote Australian Aboriginal community. Clin Sci. 2004;106(2):1218.
  • 4
    National Centre for Monitoring Cardiovascular Disease. Heart, Stroke and Vascular Diseases – Australian Facts 2004. Canberra ( AUST ) : Australian Institute of Health and Welfare. AIHW; 2004.
  • 5
    Wang Z, Hoy WE. Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people Med J Aust. 2005;182(2):669.
  • 6
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):9739.
  • 7
    Ridker PM, Bassuk SS, Toth PP. C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep. 2003;5(5):3419.
  • 8
    Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107(3):3701.
  • 9
    Tall AR. C-reactive protein reassessed. N Engl J Med. 2004;350(14):14502.
  • 10
    Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):138797.
  • 11
    Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102(18):21658.
  • 12
    Li SH, Szmitko PE, Weisel RD, Wang CH, Fedak PW, Li RK, et al. C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation. 2004;109(7):8336.
  • 13
    Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107(13):178390.
  • 14
    Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107(3):3917.
  • 15
    Hoy WE, Wang Z, VanBuynder P, Baker PR, Mathews JD. The natural history of renal disease in Australian Aborigines. Part 1. Changes in albuminuria and glomerular filtration rate over time. Kidney Int. 2001;60(1):2438.
  • 16
    STATA: statistical software [computer program]. Version 9.0. College Station ( TX ) : StataCorp; 2005.
  • 17
    Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):23742.
  • 18
    Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):83643.
  • 19
    Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351(25):2599610.
  • 20
    Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112(1):2531.
  • 21
    Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis. 2006;187(2):41522.
  • 22
    Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49(21):212938.
  • 23
    Wilson PW, Nam BH, Pencina M, D’Agostino RB Sr, Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med. 2005;165(21):24738.
  • 24
    Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288(5):H203141.
  • 25
    Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440(7088):121721.
  • 26
    Jae SY, Fernhall B, Heffernan KS, Jeong M, Chun EM, Sung J, et al. Effects of lifestyle modifications on C-reactive protein: contribution of weight loss and improved aerobic capacity. Metabolism. 2006;55(6):82531.
  • 27
    Andersson J, Boman K, Jansson JH, Nilsson TK, Lindahl B. Effect of intensive lifestyle intervention on C-reactive protein in subjects with impaired glucose tolerance and obesity. Results from a randomized controlled trial with 5-year follow-up. Biomarkers. 2008;13(7):6719.
  • 28
    Currie BJ, Carapetis JR. Skin infections and infestations in Aboriginal communities in northern Australia. Australas J Dermatol. 2000;41(3):13945.
  • 29
    Carapetis J, Gardiner D, Currie B, Mathews JD. Multiple strains of Streptococcus pyogenes in skin sores of aboriginal Australians. J Clin Microbiol. 1995;33(6):14712.